NEWS

TRACT Therapeutics, Inc. Receives Orphan-Drug Designation for TRK-001 from the U.S. FDA

TRACT Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company

SCIENTIFIC REPORTS, A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells in Living Donor Kidney Transplants” April...

TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™ to Collect and Bank a Patient’s Immune Cells for Future Treatment...

Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in De Novo Living Donor Kidney Transplant Recipients Download the...

TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial Using a Patient’s Immune Cells to Prevent Organ Rejection CHICAGO -...

Results of a Phase 1 Trial of Treg Adoptive Cell Transfer (TRACT) in de novo living donor kidney transplant recipients. Download the full...

TRACT Therapeutics, Inc. Completes Phase I Safety Trial Using a Patient’s Immune Cells to Prevent Organ Rejection Safety Data Presented...

International Society for Cellular Therapy, Miltenyi Biotec Corporate Symposium, May 27, 2015, Las Vegas, NV Ann LeFever, PhD to present...

“A kidney transplant that lasts for life. It’s the ultimate goal. But the drugs that keep a donor organ going also pose the greatest...